GE HealthCare (GEHC) announced that Cardiovascular Associates of America, or CVAUSA, the largest network of private cardiology groups in the U.S., plans to broaden its adoption of GE HealthCare’s FDA-approved cardiac positron emission tomography radiotracer Flyrcado injection, across approximately 25 sites following a successful pilot at Cardiovascular Medicine in Davenport, Iowa. This planned rollout marks a significant milestone for advancing PET myocardial perfusion imaging in community cardiology settings and reflects growing confidence in Flyrcado’s role in shaping the future of cardiac imaging.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- Hold Rating Justified for GE Healthcare Technologies Amid Limited Impact from Generic Omnipaque Launch
- GE HealthCare, RadNet to expand AI collaboration
- GE HealthCare management to meet with Piper Sandler
- GE Healthcare’s Earnings Call: Growth Amid Challenges
- GE HealthCare price target lowered to $87 from $89 at Wells Fargo